jRCT2031230123已完成不适用
An Open Label Study Assessing the Safety and Tolerability of SB206 in Japanese subjects with Molluscum Contagiosum
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 2age old over 至 No limit（—）
- 性别
- All
入选标准
- •Japanese patients with molluscum contagiosum aged 2 years or older and in good general health;
- •Patients who are able to understand and follow study instructions or who have support from the parent or legal guardian;
- •Patients who have a documented informed consent from voluntary signed by subject or a representative (parent or legal guardian) who received full explanations regarding the objectives and details of the study and the study drug."
排除标准
- •Patients who have molluscum contagiosum only in periocular area;
- •Patients who have received any treatment for molluscum contagiosum during the 14 days prior to Baseline;
- •Patients who are suspected to be immunosuppressed or have immunodeficiency disorder, or are on immunosuppressive treatment;
- •Patients who have history or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data."
结局指标
主要结局
-
Safety and Tolerability
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
2 期
An Open Label Study Assessing the Safety and Tolerability of SB206 in Japanese subjects with Molluscum ContagiosumMolluscum contagiosumJPRN-jRCT2031230123Yoshiyuki Kaneko20
进行中（未招募）
不适用
Open-Label Safety Study of MF/F in AsthmaPersistent AsthmaEUCTR2014-004583-38-Outside-EU/EEASchering-Plough Research Institute, a division of Schering Corporation49
已完成
1 期
Thorough QT/QTc Study of S-600918 in Healthy Adult ParticipantsJPRN-jRCT2080225293SHIONOGI & CO., LTD.40
进行中（未招募）
不适用
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in CanadaEUCTR2015-003491-69-Outside-EU/EEAovartis Pharmaceuticals4
已完成
不适用
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.-D638 Anaemia in other chronic diseases classified elsewhereAnaemia in other chronic diseases classified elsewhereD638PER-041-08PRODUCTOS ROCHE Q.F.S.A.,